Drug Classes & How They Work

  • Mealtime insulins are categorized into ultra-rapid-acting formulations, rapid-acting insulin analogs, and short-acting regular human insulin (1.1) (2.1) (4.1).
Mealtime Insulin Subtype Active Ingredient & Trade Examples Onset & Peak Action Duration & Pre-Meal Timing
Ultra-rapid-acting aspart Insulin aspart + niacinamide (Fiasp) Onset 2.5-15 min; peak 1-2 hr 3-5 hr duration; dosed at the start of a meal or within 20 minutes after starting to eat (2.1) (3.1)
Rapid-acting insulin lispro Insulin lispro (Humalog, Admelog) Onset 15-30 min; peak 1-2.5 hr 3-5 hr duration; dosed within 15 minutes before a meal or immediately after eating (1.1) (2.1)
Rapid-acting insulin aspart Insulin aspart (NovoLog / NovoRapid, Trurapi) Onset 10-20 min; peak 1-3 hr 3-5 hr duration; dosed 5 to 10 minutes before a meal or used in CSII insulin pumps (1.1) (2.1)
Rapid-acting insulin glulisine Insulin glulisine (Apidra) Onset 15-20 min; peak 1-2 hr 3-4 hr duration; zinc-free formulation dosed within 15 minutes before or 20 minutes after starting a meal (2.1) (4.1)
Short-acting regular human insulin Regular insulin rDNA (Humulin R, Novolin ge Toronto) Onset 30-60 min; peak 2-4 hr 6-8 hr duration; must be injected 30 minutes prior to eating to align peak action with meal absorption (1.1) (2.1)

Fast-acting insulin: Clinical Overview & Scope

  • Fast-acting (prandial or bolus) insulins are engineered to replicate the physiological first-phase insulin surge secreted by healthy pancreatic beta cells in response to carbohydrate absorption during meals (1.1) (2.1).

  • In unmodified regular human insulin, individual insulin molecules self-associate around zinc ions into six-molecule clusters (hexamers) in the subcutaneous tissue, delaying capillary absorption for 30 to 60 minutes (2.1) (3.1).

  • Rapid-acting insulin analogs, insulin lispro, insulin aspart, and insulin glulisine, modify one or two amino acids on the B-chain to destabilize hexamer formation, allowing immediate dissociation into monomers that enter the bloodstream within 10 to 20 minutes of injection (1.1) (2.1).

  • Representative medications in our fast-acting insulin directory include Apidra (Insulin Glulisine), Fiasp (Insulin Aspart), Humalog (Insulin Lispro), Novolog (Insulin Aspart), Novorapid Penfill (Insulin Aspart), Kirsty (Insulin Aspart) (1.1).

Dosage Forms, Release Profiles & Devices

  • Rapid-acting mealtime insulins are clear, colorless aqueous solutions available in 10 mL U-100 vials, 3 mL cartridges (PenFill / Humalog cartridges), and 3 mL prefilled disposable pens (KwikPen, Junior KwikPen with 0.5-unit increments, FlexTouch, FlexPen, and SoloStar) (2.1) (4.1).
  • In continuous subcutaneous insulin infusion (CSII) external insulin pumps, rapid-acting analogs (lispro, aspart, glulisine) are the standard of care; insulin in a pump reservoir must be changed according to the specific manufacturer schedule (typically every 48 to 72 hours, or earlier if exposed to temperatures above 37°C/98.6°F) to prevent fibril precipitation and catheter occlusion (1.1) (2.1).
  • Note that Canadian NovoRapid and U.S. NovoLog are manufactured by Novo Nordisk with the identical active ingredient (insulin aspart rDNA 100 units/mL), and Novolin ge Toronto is the Canadian trade name for short-acting regular human insulin (Novolin R) (2.1) (4.1).

Key Safety, Storage & Monitoring Points

  • Because rapid-acting analogs begin lowering blood glucose within 15 minutes of injection, patients must have their meal ready to eat before injecting; injecting a rapid-acting insulin and then delaying or skipping food intake will precipitate acute post-injection hypoglycemia (1.1) (2.1).
  • Conversely, short-acting regular human insulin (Humulin R / Novolin ge Toronto) has a slower 30-to-60-minute onset and a longer 6-to-8-hour tail, which increases the risk of late postprandial hypoglycemia between meals if doses are "stacked" too closely together (1.1) (3.1).
  • Fast-acting insulins must always be visually inspected before each injection: the liquid must be crystal clear and colorless, and any vial or pen showing cloudiness, clumping, frosting, or discoloration must be discarded (2.1).

Ordering & Prescription Checklist for U.S. Patients

  • Match your prescription details: Confirm the active ingredient name, exact milligram or microgram strength, release profile, and package quantity on your U.S. prescription (2.1) (4.1).
  • Licensed pharmacist review: Every order undergoes a dosing, strength, and drug-interaction check in under 1 business day, followed by a mandatory pharmacist consultation before dispatch (3.1).
  • Transparent USD pricing and shipping: Room-temperature medications ship for $14.99 USD flat rate and cold-chain medications ship in $29.99 USD insulated coolers via tracked Canada Post and USPS delivery.
  • Need help matching a product or transferring an Rx? Call 1-888-868-1920 (Monday - Friday: 9:00AM - 6:00PM; Saturday - Sunday: Closed) or review our step-by-step ordering guide and prescription requirements.

Frequently Asked Questions

Are NovoRapid and NovoLog the exact same insulin?

Yes. NovoRapid is the registered trade name in Canada and Europe, and NovoLog is the registered trade name in the United States for Novo Nordisk’s insulin aspart (100 units/mL) (2.1) (4.1). Both have the identical amino acid structure, concentration, and onset/peak profile.

How does Fiasp differ from standard NovoRapid / NovoLog (insulin aspart)?

Fiasp contains the same active molecule (insulin aspart) but adds niacinamide (vitamin B3) to accelerate initial subcutaneous absorption across capillary membranes, plus L-arginine as a stabilizer (2.1) (3.1). This allows Fiasp to appear in the bloodstream within ~2.5 minutes and be injected right at the start of a meal.

What is "insulin stacking" with fast-acting mealtime insulin?

Rapid-acting insulin continues working for 3 to 5 hours after an injection (and regular human insulin lasts 6 to 8 hours) (1.1) (2.1). Taking a second full correction dose within 2 hours of a previous mealtime injection, before the first dose has finished working, causes the two doses to overlap ("stack") and can trigger severe hypoglycemia.

Related Practical Comparison Guides

References & Official Clinical Sources

Pharmacological classifications, mechanism comparisons, dosing-form distinctions, and clinical safety notes for fast-acting insulin are compiled from official regulatory prescribing monographs and medical practice guidelines:

Need help finding your medication? Call 1-888-868-1920.

Call 1-888-868-1920Help